Be Bio

Be Biopharma is a pioneer in the field of Engineered B Cell Medicines (BeCMs), a new class of cellular therapies designed to treat a wide range of diseases. By leveraging the natural ability of B cells to produce large quantities of proteins, the company develops therapies that can provide durable, redosable, and titration-capable protein expression without the need for toxic conditioning regimens. Their platform focuses on engineering B cells to secrete therapeutic proteins for applications in rare diseases, oncology, and infectious diseases. The company's lead programs target Hemophilia B and Hypophosphatasia, aiming to transform the treatment landscape for patients requiring chronic protein replacement.